A Practical Approach to Elevated Lipoprotein(a): Is There a Role for Nutraceuticals in Clinical Practice?

Lipoprotein(a) [Lp(a)] is a lipoprotein particle predominantly determined by genetic factors and independently associated with atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Although its recognition as a risk modifier has increased, few widely available interventions substantially lower its concentrations. Statins and ezetimibe do not meaningfully reduce Lp(a), whereas PCSK9 inhibitors produce moderate reductions, and therapies directed at apolipoprotein(a) remain under development or cardiovascular outcome evaluation. In this setting, nutraceuticals have been proposed as accessible alternatives or adjuncts. This practical review summarizes the available clinical evidence for L-carnitine, coenzyme Q10, flaxseed, curcumin, berberine, pectin, Ginkgo biloba, Xuezhikang, N-acetylcysteine, phytosterols, omega-3 fatty acids, and other natural products. The most consistent evidence for Lp(a) lowering comes from meta-analyses of randomized trials of L-carnitine, coenzyme Q10, and flaxseed, although absolute effects are generally modest. Pectin, Ginkgo biloba, and Xuezhikang produced larger reductions in individual studies, but with low certainty and limited replication. No evidence demonstrates that nutraceutical-mediated Lp(a) lowering reduces cardiovascular events. We propose a pragmatic approach centered on global cardiovascular risk stratification, intensive control of LDL-C and other modifiable risk factors, and, only after shared decision-making, an individualized trial of one nutraceutical followed by laboratory reassessment after 8-12 weeks. Nutraceuticals should neither replace proven therapies nor be used as an isolated strategy in individuals at high or very high risk.